ABSTRACT: Objectives: Many US children use complementary health approaches (CHAs), including some modalities that may be ineffective, unsafe, and/or costly. Yet, little is known about the prevalence and correlates of CHA use among children with developmental disabilities (DDs), as well as parent nondisclosure of CHAs used for children with DDs to health care providers. We, therefore, aimed to profile the use and nondisclosure of CHAs among US children with DDs. Methods: We analyzed data from the 2012 National Health Interview Survey, which included the most recent Child Complementary and Alternative Medicine Supplement. The study sample was comprised of 2141 children with DDs aged 4 to 17 years. Results: Nearly one-quarter (23%) of US children with DDs used CHAs. Among those with a personal health provider, 42% of parents did not disclose some or all CHAs used to the child's provider. The adjusted odds ratios of using CHAs were greater among those with female sex, higher household income, residences not in the South, difficulty accessing care, or comorbid conditions. CHA was most commonly used because "it is natural." Nondisclosure was associated with female sex, older age, having no functional limitations, less conventional services use, and use of fewer CHAs. The most common reason for nondisclosure was that the child's provider did not ask.
however, vary in efficacy, take time to show noticeable positive effects, or may not alleviate all concerning associated symptoms (e.g., gastrointestinal problems for children with ASD). Together with other factors, these circumstances may influence a family's decision to use complementary health approaches (CHAs) for their child with DDs.
Complementary health approaches (also referred to as complementary and alternative medicine) encompass a wide array of modalities developed outside or parallel to mainstream medicine. 7 The National Center for Complementary and Integrative Health currently categorizes CHAs as natural products (e.g., specific vitamins and herbal supplements), mind and body practices (e.g., qigong and yoga), and other approaches (e.g., special diets and homeopathy). 7 CHAs are typically used with conventional health services. 7 At present, limited evidence exists regarding the efficacy and/or safety for many CHAs used to treat DD symptoms in children. [8] [9] [10] [11] [12] [13] The CHAs most commonly used have been previously assessed among certain condition-based subgroups of children with DDs. For example, children with ASD are commonly reported to use special diets (e.g., gluten and/or casein free), [14] [15] [16] [17] [18] certain natural products (e.g., specific vitamins/minerals and nonvitamin supplements such as probiotics), and/or mind and body practices (e.g., chiropractic or osteopathic manipulation). [14] [15] [16] [17] [18] Children with ADHD are reported to frequently use mind and body practices (e.g., chiropractic or osteopathic manipulation and massage therapy), special diets, and/or some natural products (e.g., specific vitamins/minerals and nonvitamin supplements). 19, 20 Similarly, children with CP are most commonly reported to use certain mind and body practices (e.g., massage therapy, aquatherapy, and hippotherapy). 21, 22 Within these subgroups, a minority of children are reported to use unsafe and/or inefficacious CHAs, such as chelation or hyperbaric oxygen therapy, in relation to their DD symptoms. Still, little is known about the types of CHAs most commonly used by children with DDs overall.
Past research also suggests that the prevalence of CHA use is higher among specific DD subgroups (e.g., ASD and ADHD) than it is among other children. 14, [17] [18] [19] [20] [23] [24] [25] That is, the use of CHAs in the larger US child population was estimated to be 12.0% in 2007 and 11.6% in 2012. 26 Recent studies using large databases estimate that 17.3% 23 to 28% 14 of children with ASD use CHAs, and approximately 25% of US youth (aged 7-17 years) with ADHD use CHAs. 20 We are, however, unaware of previous studies that have estimated the prevalence of CHA use among US children with DDs more broadly.
Greater knowledge of what factors are related to CHA use among children with DDs is additionally needed. Previous research has identified some correlates of CHA use (e.g., age, symptomatology, and parent education), again though, only among certain condition-based subgroups of children with DDs. 14, 17, 18, 20, 21, 23, 27 For instance, younger versus older children with ASD or CP have been found to be more likely to use CHAs. 18, 21 Across these 3 DD subgroups (i.e., ADHD, ASD, and CP), severity of symptoms or comorbidity has also been associated with the use of CHAs. 14, 17, 20, 21 Higher parent education versus lower parent education has additionally been associated with CHA use in studies of children with ADHD, ASD, or CP. 17, 18, 20, 21, 27 Some research also suggests that the use of certain conventional health services, particularly prescription medication, may be associated with the use of CHAs among children with ASD or ADHD. 17, 18, 20, 27 Yet, the extent to which a more comprehensive set of factors are associated with the use of CHAs among US children with DDs has not been determined.
Because CHAs are most commonly used along with conventional health services for children, pediatric health care providers are recommended to routinely communicate with families about and monitor CHAs used for children. 28, 29 A critical piece of this communication is a parent's disclosure of CHAs used for their child to the child's health care provider(s). Limited research has, however, examined how often parent disclosure of CHAs used for children occurs and what factors are related to disclosure.
Findings from several studies suggest that nondisclosure of CHAs used in pediatric populations, including children with ADHD or asthma, occurs frequently. 19, 30, 31 Younger child age (,6 years old), 30 use of mind and body practices, 30 parent non-CHA use, 30 and high parent-provider relationship quality 31 have been shown to be associated with parent disclosure of CHAs used for children. The most frequently reported reason for nondisclosure in one study of children with asthma was that the parent did not think the child's provider needed to know. 31 Disclosure of CHAs used for children with ASD has also been explored in two recent qualitative studies. One of these studies identified barriers to and facilitators of disclosure of CHAs used for children with ASD from parents' perspectives, 32 and the other study described the use of CHAs as an influence on shared decision making from the perspectives of parents of children with ASD and primary care pediatricians. 33 Findings from these qualitative studies suggest that disclosure and subsequent discussion of CHAs used for children with ASD can be challenging due to a number of factors such as provider attitudes and/or knowledge regarding CHAs, as well as parent-provider relationship quality. Taken together, past research provides some indication of the frequency with which parent nondisclosure of CHAs used occurs in pediatric health care settings; however, further research is needed to better understand parent nondisclosure of CHAs used for children including in those with DDs.
Knowledge regarding the use and nondisclosure of CHAs among children with DDs is currently limited. Greater understanding regarding the prevalence and correlates of CHA use and nondisclosure for children with DDs is needed to improve health care delivery and quality, specifically in terms of how information about CHAs is transferred between families of children with DDs and health care providers. Increased knowledge of CHA use and nondisclosure among children with DDs may also inform the development of future studies about pediatric health services utilization and outcomes, as well as intervention studies intended to promote family and provider communication about the use of CHAs and shared decision making more broadly. For these reasons, this study aimed to determine the prevalence and correlates of CHA use and nondisclosure among US children with DDs. This study is novel because it applied the Complementary and Alternative Medicine Healthcare Model to comprehensively examine both the use and nondisclosure of CHAs among a large and nationally representative sample of US children with DDs, using one of the most extensive data sources presently available on the use and nondisclosure of CHAs in the United States.
METHODS

Study Design and Data Source
We analyzed parent-reported data from the 2012 National Health Interview Survey (NHIS). The 2012 NHIS is the most recent NHIS to include the Child Complementary and Alternative Medicine (CAM) Supplement Questionnaire. The supplement, sponsored by the National Center for Complementary and Integrative Health, was intended to provide nationally representative information on CAM use among children aged 4 to 17 years. 34 The final response rate was 69.7%. 35 The institutional review board at the affiliated university determined that this study did not require review.
Sample
Of children aged 4 to 17 years (n 5 10,185) for whom the 2012 NHIS Child CAM Supplement Questionnaire was completed, 2141 were determined to have 1 or more developmental disabilities (DDs). To determine DD status, we used the Centers for Disease Control and Prevention's current DD definition 2 and relevant past research. 1, 3 Specifically, DD status was based on affirmative responses by the child's parent to a series of questions in the 2012 NHIS Sample Child Core asking if the child had attention deficit/hyperactivity disorder, autism spectrum disorder, cerebral palsy, Down syndrome, intellectual disability, seizures, stammering or stuttering, moderate to profound hearing loss, visual impairment including blindness, learning disorders, or other developmental delays.
Predisposing, Enabling, and Health Care Need Factors
We used the CAM Healthcare Model, 36 a modification to the Behavioral Model of Health Services Utilization (the Behavioral Model), 37 as the theoretical basis for determining factors potentially correlated with the use and nondisclosure of complementary health approaches (CHAs). The CAM Healthcare Model includes factors adapted from the Behavioral Model that are theorized to influence the use of CHAs with or without conventional health services, and in turn, health care outcomes (e.g., quality of life). Factors potentially influencing the use of CHAs more specifically include those that predispose an individual to use CHAs (e.g., sex, age, and education), enable an individual to use CHAs (e.g., income and health insurance coverage), or influence their need for CHAs (e.g., condition symptoms and perceived health status).
To operationalize predisposing, enabling, and health care need factors for this study, we used these definitions to identify relevant variables available in the data source. Predisposing factors included child age, sex, race and ethnicity, parent education, and family structure. Enabling factors included household income relative to the federal poverty level, health insurance coverage, household employment, and census region. Health care need factors were any problem or delay accessing conventional health care (e.g., prescription medication); current use of 3 or more conventional health care services (i.e., office visits, specialty care, emergency department visit, mental health care, therapy services, prescription medication, special education, or early intervention); and comorbidity per the 38 chronic conditions asked about in the 2012 NHIS. In addition, health care need factors included functional limitations status based on if the child had any impairment limiting his or her physical abilities (e.g., walking); used special equipment (e.g., wheelchair); or had difficulties with emotions, concentration, behavior, or getting along with others that limited his or her daily activities. To account for confounding when examining nondisclosure correlates, the number of CHAs used in the past year dichotomized at the median of 1 was included.
Use and Nondisclosure of Complementary Health Approaches
Children were determined to have used any CHA if they had at least 1 affirmative response to items asking, "During the past 12-months, did [child] use.?" They were asked about chelation, Ayurveda, acupuncture, qigong, hypnosis, biofeedback, energy healing, craniosacral therapy, naturopathy, tai chi, traditional healers (e.g., Native American healer), movement therapy (e.g., Pilates), guided imagery, meditation, special diets (e.g., vegetarian or vegan), homeopathy, massage therapy, yoga, chiropractic or osteopathic manipulation, herbal or nonvitamin supplements (e.g., fish oil), specific minerals (i.e., calcium, magnesium, iron, chromium, zinc, selenium, and potassium), and specific vitamins (i.e., A, B, C, D, E, H, and K). To have been counted as using acupuncture, Ayurveda, biofeedback, chelation, chiropractic or osteopathic manipulation, craniosacral therapy, energy healing therapy, hypnosis, massage, movement and exercise techniques, or naturopathy, the child had to have seen a practitioner for the modality in the past 12 months or the child was reported to have used the given modality in the past 12 months. As per past research, we did not consider children who were only indicated to have used multivitamins or multiminerals in the past 12 months as having used any CHA. 26 To further characterize CHA use, we additionally examined the reasons for the use of CHAs that were asked about. In the survey, parents were asked to select up to 3 modalities that children were reported to have used in the past 12 months that the parent considered to be most important for the child's health. Parents were not able to select multivitamins/minerals, specific vitamins, specific minerals, or chelation in this survey section. Then, for each modality selected as being most important for the child's health, 14 reasons for use were subsequently asked about (Fig. 1A) .
Complementary health approach nondisclosure was only assessed among children with a usual source of health care and a personal health provider, defined as a health professional who knew the child well and was familiar with the child's health history (e.g., general doctor). To have been asked about CHA nondisclosure, the child additionally needed to have used 1 or more CHAs from the subset of modalities that reasons for use were asked about. The following item was asked for up to 3 of these modalities, which were reported as being most important for the child's health, "During the past 12 months, did you let [child]'s personal health provider know about [his/her] use of [modality]?" Nondisclosure of any CHA was defined as the parent saying "No" for any of the modalities asked about. Because correlates of nondisclosure of any versus all CHAs asked about may differ among children with DDs, we also included a nondisclosure of all CHA measures (i.e., nondisclosure was reported for all modalities asked about). When any nondisclosure was reported by parents, 8 reasons for nondisclosure were subsequently asked about (Fig. 1B) . We examined 6 reasons for nondisclosure, collapsing 3 reasons into a single variable about negative provider reaction, because of low response frequency and content similarity.
Analysis
To describe the sample and estimate the prevalence of CHA use and nondisclosure among US children with DDs, descriptive statistics were first computed for all variables of interest. We also computed CHA use by DD status to further contextualize the prevalence of CHA use for children with DDs. Bivariate statistics were then computed to determine differences in the distributions of predisposing, enabling, and health care need variables by the use and nondisclosure of CHAs. Bivariate analysis results informed that 3 multivariable logistic regression models fit to determine adjusted associations of predisposing, enabling, and health care need factors with (1) any CHA use, (2) nondisclosure of any CHA, and (3) nondisclosure of all CHAs. Factors that had an unadjusted association with CHA use and/or nondisclosure significant at a p , 0.10 level were initially included in the respective multivariable model but were only retained if their association remained statistically significant at the p , 0.05 level. Given sample size constraints, we descriptively examined reasons for CHA use and nondisclosure. We weighted analyses as per National Center for Health Statistics (NCHS) guidance 35 and performed all analyses in Stata 14.2.
RESULTS
Population Characteristics
The sample represented an estimated 12,382,376 US children with developmental disabilities (DDs) aged 4 to 17 years. The most common DD was attention deficit/ hyperactivity disorder (47.4%) followed by learning disabilities (39.5%), other DDs (22.9%), visual impairment (15%), moderate or profound hearing loss (11.9%), stuttering or stammering (8.6%), autism spectrum disorder (6.4%), intellectual disability (5.9%), seizures (3.4%), and cerebral palsy (1.4%). The mean child age was 11 years (SD 5 3.8 years). Many children with DDs were male, non-Hispanic white, had at least 1 parent with more than a high school education, had a household income level above the federal poverty level, had 1 or more working adults in their household, had no problems or delays accessing conventional care, and had comorbid conditions ( Table 1) . For children with DDs, specific vitamins (14.7%), herbal supplements (8.1%), and specific minerals (7.7%) were the most commonly used modalities, followed by chiropractic or osteopathic manipulation (3.2%). Certain modalities that can be unsafe, such as special diets (;1%), were infrequently reported to be used by children with DDs, and no children with DDs were reported to have used chelation. Although bivariate analysis results showed statistically significant associations of CHA use with child age, race and ethnicity, parent education, health insurance, household employment, conventional care use, and functional limitations status, these associations did not remain statistically significant in the multivariable analysis. Multivariable regression results showed higher adjusted odds of CHA use for children with DDs who were female, had higher household income, did not live in the South, experienced any problem or delay accessing conventional care, and had 1 or more comorbid chronic conditions (Table 2). Among children with DDs who used 1 or more of the select CHA modalities, the most frequently reported reasons for use were because it is natural, for the child's general wellness or disease prevention, and because it treats the and cause not just the symptoms (Fig. 1A) .
Use of Complementary Health Approaches
1. Characteristics of US Children with DDs Aged 4-17 Years (n 5 2141)
Nondisclosure
Among US children aged 4 to 17 years with DDs who used any CHA in the past year and had a personal health provider, nondisclosure of any CHA used was reported for an estimated 533,333 or 41.9% (95% CI: 34.2-50.0) of children. Nondisclosure of all CHAs used was reported for an estimated 461,750 or 36.2% (95% CI: 28.3-45.0) of children with DDs. For children with DDs, the most frequently nondisclosed modalities were herbal supplements (i.e., fish oil, melatonin, and probiotics), certain mind and body practices (i.e., yoga, tai chi, qigong, chiropractic, or osteopathic manipulation), and homeopathy (data not shown). Multivariable regression results demonstrated higher adjusted odds of nondisclosure of any CHA used for children with DDs who were female or had no functional limitations (Table 3 ). Higher adjusted odds of nondisclosure of all CHAs used were found for children with DDs who were older in age, used 2 or fewer conventional health care services, and only used 1 modality of CHAs (Table 3 ). The most frequently reported nondisclosure reason was that the child's health provider did not ask (Fig. 1B) .
DISCUSSION
This study is one of the first to examine the prevalence and correlates of complementary health approach (CHA) use and nondisclosure among US children with developmental disabilities (DDs). Our study found higher CHA use prevalence for US children with DDs (23.3%) compared to those without DDs (19.8%). Previous research using data from other databases among subgroups of US children with DDs has shown a prevalence of CHA use close to that of this study, ranging from 17.3% 23 to 28.0% 14 for children with autism spectrum disorder (ASD) and 10.2% 25 to 24.7% 20 for children with attention deficit/ hyperactivity disorder (ADHD). Variability in prevalence estimates of CHA use may be due in part to differences in how CHA use is measured (e.g., the exclusion of specific vitamins and/or specific minerals from the definition of CHAs), as well as how children are sampled. Consistent measurement and sampling are, therefore, needed in future research intended to determine time trends in CHA use among children with DDs.
Being female, having higher household income, not living in the South, having difficulty accessing health care, and having a comorbidity were each associated with greater odds of CHA use. These findings are consistent with past research, suggesting that female versus male children with mental health conditions including ADHD 20 are more likely to use CHAs. Past research similarly shows that children with ADHD who have higher household income are more likely to use CHAs. 20, 25 Our study findings regarding regional variation in CHA use among children with DDs are also consistent with past research, demonstrating that children with ADHD 25 or ASD 23 in the South are less likely to use CHAs. Past research additionally shows that various markers of elevated health care needs (e.g., problems accessing care, service use, comorbidity, and symptom severity) are associated with greater CHA use in DD subgroups (e.g., ASD and ADHD), 14, 20, 25 and our study also showed that problems accessing health care and comorbidity were associated with greater odds of CHA use among children with DDs. Future research is needed to determine how different aspects of health care needs (e.g., changes in the need for certain conventional DD treatments) may interact over time in relation to CHA use for children with DDs.
The most frequently reported reason for use (i.e., it is natural) among children with DDs who used any CHA aligns with some previous research, demonstrating that parents use CHAs because they believe that the CHA is safer than other treatments (e.g., medication), 24 although this may not be true. We also found that the use of CHAs to treat the cause and not just the symptoms was another frequently reported reason. A potential rationale for CHA use by children with ASD and other neurodevelopmental disorders-particularly the use of biomedical modalities-is that they are believed to address underlying disease mechanisms (e.g., oxidative stress and immune abnormalities). 13 Our study suggests that this belief may contribute to CHA use in children with DDs more broadly. Still, how these and other beliefs, together, drive patterns of conventional health care and CHA use in children with DDs remains largely unstudied and an area for future research.
We found that nondisclosure was relatively common for some or all modalities reported to be most important for the child's health. Past studies 19, 30, 31 have found higher nondisclosure rates for other specific populations (e.g., children with asthma). Methodological differences (e.g., nonprobability vs probability sampling) may account for some of this variation, or it may be that children with DDs are relatively well connected to the health system and are more likely to disclose CHA use. We also found discrepancies in the factors significantly associated with nondisclosure of any versus all CHA modalities used by children with DDs. Specifically, although nondisclosure of any CHA may be more likely for female children or those without functional limitations, nondisclosure of all modalities may most commonly occur among older children, those receiving fewer conventional care services, or those using few CHA modalities. Overall, our study's findings align with past research, showing that younger age, more severe symptomatology, and routine conventional health services use may prompt disclosure. Sex has not, however, been a characteristic previously identified as potentially influencing nondisclosure among children with DDs, suggesting that greater exploration of sex-based differences in family-provider communication about CHA use in children with DDs is needed. Like past research, 30, 31, 38 the most frequently reported reasons for nondisclosure in this study were that the child's health provider did not ask or that the parent felt the child's provider did not need to know, pointing to a need for improved family-provider communication about CHAs and greater education of families and providers about DD treatment options including CHAs. Past research shows that some pediatric providers encourage the use of certain CHAs (e.g., fatty acids and melatonin) for children with ASD and that most of these providers inquire about CHA use and would like to receive more training about CHAs. 39 Relatedly, limited provider knowledge and/or negative attitudes about CHAs may contribute to nondisclosure and ultimately greater discord in shared decision making between families of children with ASD and their health care providers. 32, 33 Additional research is needed to determine how family-provider communication and other aspects of pediatric health care visits (e.g., visit questionnaires asking about CHA use and provider prompts to ask about CHAs in the electronic health record system) could be used to reduce nondisclosure and potentially improve pediatric health care quality more broadly (e.g., receipt of routine immunizations and use of antibiotics).
Our findings should be interpreted with several limitations in mind. Foremost, the cross-sectional design precludes causal inferences from being drawn. Descriptive results on reasons for CHA use and nondisclosure do, however, provide some insights into the motivations for these behaviors. Future longitudinal and mixed methods research is needed to better understand why families use CHAs for children with DDs and do not disclose it to their child's health provider. Although the definitions used to construct measures of DD status, as well as CHA use and nondisclosure, are congruent with past research, measurement variability across the entire body of relevant research may contribute to differences in findings. For example, the 2012 National Health Interview Survey (NHIS) Complementary and Alternative Medicine Supplement did not ask about all potential modalities used (e.g., hyperbaric oxygen therapy and essential oils), and this may contribute to differences in estimates of CHA use prevalence across studies. In addition, nondisclosure of CHAs used was only assessed for a subset of children in the 2012 NHIS (i.e., those with a usual source of care and personal health provider who used the CHA asked about). Further research is, therefore, needed to better understand nondisclosure among the broader population of children with DDs who may not have a health provider and/or use modalities that were not asked about. Although the time frame of all NHIS items used to assess CHA use and nondisclosure was the past 12 months, the potential for recall bias still exists in terms of underreporting or overreporting. Other data sources such as information available from children's electronic health records and/or patient portals may be considered in future research insofar as they may be able to provide additional and potentially more recent insights into CHA use and disclosure among children with DDs.
CONCLUSION
Complementary health approach (CHA) use is prevalent among children with developmental disabilities (DDs) nationwide. The most common reason for CHA use ("it is natural") reflects parents' perception that CHAs may be safe. This perception may be consistent with current scientific evidence for some CHAs used to treat DDs, whereas for other CHAs, it may not be. Families of children with DDs may view health care providers as information resources or brokers regarding DD treatment options, including CHAs. Health care providers may, however, possess limited knowledge of CHAs. 39 Increased education for health care providers about CHAs is, therefore, needed. Greater knowledge of CHAs among health care providers may, in turn, help families to better understand the safety and efficacy of CHAs along with other DD treatment options. Disclosure of CHAs is necessary for shared treatment decision making to occur. Our study revealed that nondisclosure may be common among children with DDs. The most frequent reasons for nondisclosure highlight a need for improved family-provider communication about CHAs specifically in terms of providers initiating dialogue about CHAs. Provider prompts in electronic health record systems to ask families about CHAs reported on intake forms, as well as brief training to enhance providers' family-centered communication in discussing health risks 40 may be used to increase disclosure. Interventions informed by this study's findings may help improve health care for children with DDs, particularly related to the use and nondisclosure of CHAs. 
